Dec 1 (Reuters) – Pfizer (PFE.N) said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of an earlier t… [+2950 chars]Read More
Pfizer pulls the plug on twicedaily obesity pill as study disappoints Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/LTWSDI6PKRO57BSYQSRPDALZDM.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6SAYBW356FLLXO2ZM3OVQDJQD4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/PNICAZMJZJODBA6FRF7HXVYCLA.jpg)